CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

Ranjana H. Advani; Ian W. Flinn; Leslie Popplewell; Andres Forero; Nancy L. Bartlett; Nilanjan Ghosh; Justin Kline; Mark Roschewski; Ann S. LaCasce; Graham P. Collins; Thu Ha Tran; Judith Lynn; James Y. Chen; Jens-Peter Volkmer; Balaji Agoram; Jie Huang; Ravindra Majeti; Irving L. Weissman; Chris H. Takimoto; Mark P. Chao; Sonali M. Smith

doi:10.1056/nejmoa1807315

Abstract

The macrophage checkpoint inhibitor 5F9 combined with rituximab showed promising activity in patients with aggressive and indolent lymphoma. No clinically significant safety events were observed in this initial study. (Funded by Forty Seven and the Leukemia and Lymphoma Society; ClinicalTrials.gov number, NCT02953509 .).

Keywords

RituximabBlockadeMedicineLymphomaHodgkin lymphomaOncologyInternal medicineReceptor

Affiliated Institutions

Related Publications

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

Frederick L. Locke , David B. Miklos , Caron A. Jacobson +28 more

Axi-cel therapy led to significant improvements, as compared with standard care, in event-free survival and response, with the expected level of high-grade toxic effects. (Funde...

2021 New England Journal of Medicine 1322 citations

Macrophages as tools and targets in cancer therapy

Alberto Mantovani , Paola Allavena , Federica Marchesi +1 more

Tumour-associated macrophages are an essential component of the tumour microenvironment and have a role in the orchestration of angiogenesis, extracellular matrix remodelling, c...

2022 Nature Reviews Drug Discovery 1513 citations

Macrophages in immunoregulation and therapeutics

Shanze Chen , Abdullah F. U. H. Saeed , Quan Liu +5 more

Abstract Macrophages exist in various tissues, several body cavities, and around mucosal surfaces and are a vital part of the innate immune system for host defense against many ...

2023 Signal Transduction and Targeted Therapy 1449 citations

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

Matthew M. Gubin , Xiuli Zhang , Heiko Schuster +24 more

The immune system influences the fate of developing cancers by not only functioning as a tumour promoter that facilitates cellular transformation, promotes tumour growth and scu...

2014 Nature 1936 citations

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer , Scott S. Tykodi , Laura Q.M. Chow +23 more

Antibody-mediated blockade of PD-L1 induced durable tumor regression (objective response rate of 6 to 17%) and prolonged stabilization of disease (rates of 12 to 41% at 24 weeks...

2012 New England Journal of Medicine 7854 citations

Publication Info

Year: 2018
Type: article
Volume: 379
Issue: 18
Pages: 1711-1721
Citations: 1052
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1052

OpenAlex

Cite This

APA Style

                            
                                
                                    Ranjana H. Advani, 
                                
                                    Ian W. Flinn, 
                                
                                    Leslie Popplewell
                                
                                et al.
                            
                            (2018). 
                            CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma. 
                            New England Journal of Medicine
                            , 379
                            (18)
                            , 1711-1721.
                            https://doi.org/10.1056/nejmoa1807315
                        

Identifiers

DOI: 10.1056/nejmoa1807315